StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
June 7, 2016 9:08 AM
Piper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval
June 7, 2016 7:50 AM
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM
Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform, $36 PT
June 7, 2016 6:40 AM
Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen
June 7, 2016 6:36 AM
Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird
June 7, 2016 6:25 AM
Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
June 7, 2016 6:16 AM
Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDA
June 6, 2016 5:45 PM
Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data
June 6, 2016 5:41 PM
